Assenagon Asset Management
DSGN icon

Assenagon Asset Management’s Design Therapeutics DSGN Stock Holding History

Assenagon Asset Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,125
Closed -$105K – 1198
2025
Q2 		$105K Sell
31,125
-5,792
-16% -$21.7K ﹤0.01% 1137
2025
Q1 		$143K Sell
36,917
-19,700
-35% -$94K ﹤0.01% 1124
2024
Q4 		$349K Sell
56,617
-289,575
-84% -$1.68M ﹤0.01% 1231
2024
Q3 		$1.86M Sell
346,192
-1,602
-0.5% -$7.53K ﹤0.01% 987
2024
Q2 		$1.17M Hold
347,794
– – ﹤0.01% 1059
2024
Q1 		$1.4M Buy
347,794
+102,567
+42% +$274K ﹤0.01% 978
2023
Q4 		$650K Sell
245,227
-2,820
-1% -$6.46K ﹤0.01% 1196
2023
Q3 		$585K Sell
248,047
-53,641
-18% -$250K ﹤0.01% 1167
2023
Q2 		$1.9M Buy
301,688
+133,473
+79% +$817K 0.01% 794
2023
Q1 		$971K Buy
+168,215
New +$1.26M ﹤0.01% 1057

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Assenagon Asset Management's DSGN Position: Q3 2025 in Review

Assenagon Asset Management sold out of Design Therapeutics (DSGN) in Q3 2025, closing a stake of 31,125 shares — an estimated $105K sold.

Assenagon Asset Management first reported a position in DSGN in Q1 2023 and held it in 10 quarters. The position peaked at $1.9M in Q2 2023. 95 funds tracked by Wall St. Rank hold DSGN as of Q3 2025.

  • Assenagon Asset Management reported no remaining Design Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 31,125 Design Therapeutics shares in Q3 2025, an estimated $105K.
  • Assenagon Asset Management first reported a position in Design Therapeutics in Q1 2023 and held it in 10 quarters.
  • Assenagon Asset Management's Design Therapeutics position peaked at $1.9M in Q2 2023.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2025.

Based on Assenagon Asset Management's 13F filing for Q3 2025, filed 7 Oct 2025.